biotech stocks

Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts

Rezolute, Inc. (NASDAQ: RZLT) is one of the most closely watched biotech movers heading into the Dec. 12, 2025 session after a pivotal clinical trial miss triggered a historic repricing of the stock. As of the latest available trading update

12 December 2025

Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Published: December 10, 2025 Olema Pharmaceuticals Stock Rallies to Fresh Highs Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), which now brands itself as Olema Oncology, is having another breakout session on December 10, 2025. During Wednesday’s trading, OLMA: Over the past 12

10 December 2025

Company News · Investor Tips · Market Trends · Pharmaceuticals · Stock Performance

Biotech Stocks Today: FDA Shifts, ASH 2025 Winners and Market Close Recap (December 9, 2025)

Biotech investors faced a dense catalyst calendar on Tuesday, December 9, 2025, as new U.S. Food and Drug Administration (FDA) signals on cell and gene therapy, fresh designations in hematologic cancers and high‑impact clinical data from the American Society of

9 December 2025

ASH 2025 · Biotech · FDA · Healthcare Stocks · Market Recap · NASDAQ:SNTI

CRISPR Therapeutics (CRSP) Stock on 7 December 2025: Latest Price, News, Forecasts and Gene‑Editing Outlook

CRISPR Therapeutics AG (NASDAQ: CRSP) is finishing 2025 in classic high‑beta biotech fashion: big science, big headlines, and big disagreement about where the stock goes next. As of the last U.S. trading session on Friday, 5 December 2025, CRSP changed

7 December 2025

Biotechnology · CRISPR · Gene Editing · Investment Analysis · Stock Market

Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

Published: December 4, 2025 Key Takeaways Wall Street Re‑rates Regeneron After Big Run — and Bigger Dupixent Story Regeneron Pharmaceuticals has suddenly become one of the most hotly debated large‑cap biotechs on Wall Street. On Thursday, December 4, 2025, multiple

4 December 2025

Biotech · Forecasts · NASDAQ:REGN · Pharmaceuticals · Price Targets · Stock Analysis

Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics’ stock exploded higher on December 3, 2025 after the biotech announced that its pivotal Phase 3 HOPE‑3 trial of Deramiocel (CAP‑1002) in Duchenne muscular dystrophy (DMD) met both its primary and key secondary endpoints. GlobeNewswire Below is a

3 December 2025

Biotechnology · Clinical Trials · Investment Analysis · NASDAQ:CAPR · Pharmaceutical Industry · Stock Market

AXSM Stock Today (Nov. 25, 2025): Axsome Therapeutics Near Record Highs on 63% Revenue Surge

New York — November 25, 2025 — Axsome Therapeutics (NASDAQ: AXSM) heads into Tuesday’s session trading just below fresh record highs, powered by blockbuster growth from its depression drug Auvelity, the launch of migraine pill Symbravo, and a rapidly expanding

25 November 2025

NASDAQ:AXSM

Arvinas (ARVN) Soars 14% as Investors Cheer Pipeline Reset and Jefferies Update

Arvinas (NASDAQ: ARVN) jumped in double digits on November 18, 2025 amid a focused pipeline reset, FDA momentum for vepdegestrant and attention at the Jefferies London Healthcare Conference. ARVN stock pops on November 18, 2025 Arvinas shares are in rally

18 November 2025

Biotech · Company Updates · Investment News · NASDAQ:ARVN · Pharmaceuticals · Stock Market

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

As of this afternoon, Galmed Pharmaceuticals shares were changing hands around $1.18, up roughly 13% on the day, with more than 41 million shares traded—massively above the stock’s usual daily volume. TipRanks What Galmed Announced Today From its headquarters in

17 November 2025

Biotechnology · Cancer Research · Investment News · NASDAQ:GLMD · Pharmaceuticals · Stock Market

Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

What Zymeworks Announced Today Before the U.S. market open on November 17, 2025, Vancouver‑based Zymeworks Inc. (ZYME) released topline Phase 3 data from its pivotal HERIZON‑GEA‑01 study, evaluating Ziihera (zanidatamab‑hrii) in first‑line treatment of HER2‑positive locally advanced or metastatic gastroesophageal

17 November 2025

Biotechnology · Cancer Research · Clinical Trials · Healthcare News · NASDAQ:BGNE · NASDAQ:JAZZ · NASDAQ:ZYME · Stock Market

Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Company Overview: Pioneering TIL Therapy in Oncology Iovance Biotherapeutics is focused on developing tumor-infiltrating lymphocyte (TIL) therapies – a novel form of immunotherapy where a patient’s own T cells, harvested from their tumor, are expanded and activated in a lab,

3 November 2025

Biotech · Cancer Research · Immunotherapy · Medical Innovation · NASDAQ:IOVA · Stock Analysis

Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash

Blockbuster Quarter Meets Stock Turbulence Apellis Pharmaceuticals, a biotech focused on complement-mediated diseases gurufocus.com, delivered standout financial results for the third quarter of 2025 – yet its stock took a beating. The company reported Q3 revenue of $458.6 million, more than

30 October 2025

Biotech · FDA Approval · Investment · Pharma News · Stock Market